CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 2,157 enrolled
Drug / intervention
Vitamin D3 +3 moredrug
Likely dose
Vitamin D3 2000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01745263
NCT01745263Phase 3Completed

Vitamin D3 - Omega3 - Home Exercise - Healthy Ageing and Longevity Trial (Acronym: DO-HEALTH)

University of Zurich·interventional·Posted Dec 10, 2012·Updated Aug 9, 2018

In Brief

A Phase 3 clinical trial evaluating Vitamin D3, Omega 3 fatty acids, and 2 other interventions for Improve Healthy Ageing in Seniors; Prevent Disease at Older Age. Completed, enrolled 2,157 participants across 7 sites in 5 countries.

Detailed Summary

The European population is aging rapidly which poses a challenge on the individual, the European societies, and health care systems. Among the most promising public health interventions that may extend healthy life expectancy at older age are vitamin D, marine omega-3 fatty acids and physical exercise. However, their individual and combined effects have yet to be confirmed in a clinical trial. The broad aim of DO-HEALTH is to prolong healthy life expectancy in European seniors. The specific aim is to establish whether vitamin D, omega-3 fatty acids, and a simple home exercise program will prevent disease at older age. To achieve these aims, DO-HEALTH will enroll 2152 community-dwelling men and women who are 70 years and older, an age when chronic diseases increase substantially. The DO-HEALTH seniors will be recruited from 7 European cities (Zurich, Basel, Geneva, Toulouse, Berlin, Innsbruck and Coimbra) and will be randomized in a 2x2x2 factorial design trial to a simple home exercise program and/or vitamin D, and/or omega-3 fatty acids, over a 3 year period. This will allow to test the individual and the combined benefit of the interventions in the prevention of 5 primary endpoints: incident non-vertebral fractures; functional decline; systolic and diastolic blood pressure change; cognitive decline; and the rate of any infection. Key secondary endpoints include incidence of hip fractures, rate of falls, severity of pain in symptomatic knee osteoarthritis, gastro-intestinal symptoms, mental and oral health, quality of life, and mortality. All clinical endpoints will be supported by a large DO-HEALTH biomarker study to evaluate the effect of the interventions at the cellular level of multi-organ function. DO-HEALTH will further evaluate reasons why or why not seniors adhere to the 3 interventions, and will assess their cost-benefit in a health economic model based on documented health care utilization and observed incidence of chronic disease. website DO-HEALTH: http://do-health.eu/wordpress/

Study Details

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 10, 2012
Enrollment StartDec 20, 2012
Primary CompletionNov 17, 2017
Study CompletionJan 19, 2018
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 13.6 years ago

Interventions

Vitamin D3drug

2000 IU/d

Omega 3 fatty acidsdrug

Ratio EPA:DHA = 1:2 1 g/d

Strength Home Exerciseprocedure

Flexibility Home Exerciseprocedure